SCHEMBL3567992

SCHEMBL3567992

O=C1C(c2ccccc2O)CCC1c1ccccc1O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
CYP3A4 P08684 2/20 0.43
ALDH1A1 P00352 2/20 0.43
POLB P06746 2/20 0.43
MAPT P10636 2/20 0.43
KDM4E B2RXH2 1/20 0.43
NPC1 O15118 1/20 0.43
CA12 O43570 1/20 0.43
GMNN O75496 1/20 0.43
EGFR P00533 1/20 0.43
CA2 P00918 1/20 0.43
LMNA P02545 1/20 0.43
FYN P06241 1/20 0.43
CA3 P07451 1/20 0.43
MMP9 P14780 1/20 0.43
HPGD P15428 1/20 0.43
ALOX15 P16050 1/20 0.43
NFKB1 P19838 1/20 0.43
CA4 P22748 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3635778 0.79 MEN1 (0.42) MEN1KMT2ACYP3A4MAPTAR
SCHEMBL7866000 0.75 MEN1 (0.46) MEN1KMT2AALDH1A1MAPTKDM4E
SCHEMBL929830 0.72 MEN1 (0.50) MEN1KMT2ACYP3A4ALDH1A1POLB
SCHEMBL3992205 0.72 MEN1 (0.50) MEN1KMT2ACYP3A4ALDH1A1POLB
SCHEMBL9818019 0.71 IDO1 (0.61) ALDH1A1LMNA
SCHEMBL5069071 0.71 ESR2 (0.50) MEN1KMT2ACYP3A4CA2RECQL
SCHEMBL5710152 0.71 PIN1 (0.51) MEN1KMT2ACA2PIN1
SCHEMBL15586434 0.70 MEN1 (0.36) MEN1KMT2ACYP3A4ALDH1A1POLB
Catechol SCHEMBL18422126 0.69
Catechol SCHEMBL30862273 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842705-B2 Curcumin analogs with anti-tumor and anti-angiogenic properties EMORY UNIVERSITY (US) 2010-11-30 US disclosed
US-20080234320-A1 CURCUMIN ANALOGS WITH ANTI-TUMOR AND ANTI-ANGIOGENIC PROPERTIES EMORY UNIVERSITY 2008-09-25 US disclosed
US-7371766-B2 Curcumin analogs with anti-tumor and anti-angiogenic properties EMORY UNIVERSITY (US) 2008-05-13 US disclosed
US-20040176384-A1 Curcumin analogs with anti-tumor and anti-angiogenic properties EMORY UNIVERSITY 2004-09-09 US disclosed
US-6664272-B2 Such as 1,5-Bis-(2, 4-difluorophenyl)penta-1,4-diene-3 -one; administering to inhibit tissue factor and vascular endothelial growth factor (VEGF) production in cancerous tissue EMORY UNIVERSITY 2003-12-16 US disclosed
EP-1242379-A1 CURCUMIN ANALOGUES FOR TREATING CANCER Emory University (US) 2002-09-25 EP disclosed
WO-2001040188-A9 CURCUMIN ANALOGUES FOR TREATING CANCER UNIV EMORY (US) 2002-07-25 WO disclosed
US-20020019382-A1 Curcumin analogs with anti-tumor and anti-angiogenic properties EMORY UNIVERSITY 2002-02-14 US disclosed
WO-2001040188-A1 CURCUMIN ANALOGUES FOR TREATING CANCER EMORY UNIVERSITY (US) 2001-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176384-A1 Curcumin analogs with anti-tumor and anti-angiogenic properties PGF, VEGFA, VHL MEN1 2002/4885KMT2A 3910/4885CYP3A4 4243/4885
US-20080234320-A1 CURCUMIN ANALOGS WITH ANTI-TUMOR AND ANTI-ANGIOGENIC PROPERTIES PGF, VEGFA, VHL MEN1 2002/4885KMT2A 3910/4885CYP3A4 4243/4885
US-20020019382-A1 Curcumin analogs with anti-tumor and anti-angiogenic properties PGF, VEGFA, VHL MEN1 2002/4885KMT2A 3910/4885CYP3A4 4243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.